STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers

RNAseq analysis and therapeutic screening

Chun Chia Cheng, Po Nien Liao, Ai Sheng Ho, Ken Hong Lim, Jungshan Chang, Ying Wen Su, Caleb Gon Shen Chen, Ya Wen Chiang, Bi Ling Yang, Huan Chau Lin, Yu Cheng Chang, Chun Chao Chang, Yi Fang Chang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Cancer stem cells are capable of undergoing cell division after surviving cancer therapies, leading to tumor progression and recurrence. Inhibitory agents against cancer stem cells may be therapeutically used for efficiently eradicating tumors. Therefore, the aim of this study was to identify the relevant driver genes that maintain cancer stemness in epidermal growth factor receptor (EGFR)-positive colorectal cancer (CRC) cells and to discover effective therapeutic agents against these genes. Methods: In this study, EGFR-positive cancer stem-like cells (CSLCs) derived from HCT116 and HT29 cells were used as study models for in vitro inductions. To identify the differential genes that maintain CSLCs, RNAseq analysis was conducted followed by bioinformatics analysis. Moreover, a panel containing 172 therapeutic agents targeting the various pathways of stem cells was used to identify effective therapeutics against CSLCs. Results: RNAseq analysis revealed that 654 and 840 genes were significantly upregulated and downregulated, respectively, in the HCT116 CSLCs. Among these genes, notably, platelet-derived growth factor A (PDGFA) and signal transducer and activator of transcription 3 (STAT3) were relevant according to the cancer pathway analyzed using NetworkAnalyst. Furthermore, therapeutic screening revealed that the agents targeting STAT3 and Wnt signaling pathways were efficient in reducing the cell viabilities of both HCT116 and HT29 cells. Consequently, we discovered that STAT3 inhibition using homoharringtonine and STAT3 knockdown significantly reduced the formation and survival of HT29-derived tumorspheres. We also observed that STAT3 phosphorylation was regulated by epidermal growth factor (EGF) to induce PDGFA and Wnt signaling cascades. Conclusions: We identified the potential genes involved in tumorsphere formation and survival in selective EGFR-positive CRCs. The results reveal that the EGF-STAT3 signaling pathway promotes and maintains CRC stemness. In addition, a crosstalk between STAT3 and Wnt activates the Wnt/β-catenin signaling pathway, which is also responsible for cancer stemness. Thus, STAT3 is a putative therapeutic target for CRC treatment.

Original languageEnglish
Article number60
JournalJournal of Biomedical Science
Volume25
Issue number1
DOIs
Publication statusPublished - Aug 2 2018

Fingerprint

STAT3 Transcription Factor
Epidermal Growth Factor Receptor
Neoplastic Stem Cells
Colorectal Neoplasms
Screening
Genes
Neoplasms
Stem cells
HCT116 Cells
HT29 Cells
Wnt Signaling Pathway
Cells
Therapeutics
Epidermal Growth Factor
Tumors
Catenins
Phosphorylation
Oncology
Neoplasm Genes
Bioinformatics

Keywords

  • Cancer stem cell
  • EGFR
  • LGR5
  • PDGFA
  • STAT3
  • Wnt

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers : RNAseq analysis and therapeutic screening. / Cheng, Chun Chia; Liao, Po Nien; Ho, Ai Sheng; Lim, Ken Hong; Chang, Jungshan; Su, Ying Wen; Chen, Caleb Gon Shen; Chiang, Ya Wen; Yang, Bi Ling; Lin, Huan Chau; Chang, Yu Cheng; Chang, Chun Chao; Chang, Yi Fang.

In: Journal of Biomedical Science, Vol. 25, No. 1, 60, 02.08.2018.

Research output: Contribution to journalArticle

Cheng, Chun Chia ; Liao, Po Nien ; Ho, Ai Sheng ; Lim, Ken Hong ; Chang, Jungshan ; Su, Ying Wen ; Chen, Caleb Gon Shen ; Chiang, Ya Wen ; Yang, Bi Ling ; Lin, Huan Chau ; Chang, Yu Cheng ; Chang, Chun Chao ; Chang, Yi Fang. / STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers : RNAseq analysis and therapeutic screening. In: Journal of Biomedical Science. 2018 ; Vol. 25, No. 1.
@article{fc25ab8b53344cd39bfaee15498e6e77,
title = "STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers: RNAseq analysis and therapeutic screening",
abstract = "Background: Cancer stem cells are capable of undergoing cell division after surviving cancer therapies, leading to tumor progression and recurrence. Inhibitory agents against cancer stem cells may be therapeutically used for efficiently eradicating tumors. Therefore, the aim of this study was to identify the relevant driver genes that maintain cancer stemness in epidermal growth factor receptor (EGFR)-positive colorectal cancer (CRC) cells and to discover effective therapeutic agents against these genes. Methods: In this study, EGFR-positive cancer stem-like cells (CSLCs) derived from HCT116 and HT29 cells were used as study models for in vitro inductions. To identify the differential genes that maintain CSLCs, RNAseq analysis was conducted followed by bioinformatics analysis. Moreover, a panel containing 172 therapeutic agents targeting the various pathways of stem cells was used to identify effective therapeutics against CSLCs. Results: RNAseq analysis revealed that 654 and 840 genes were significantly upregulated and downregulated, respectively, in the HCT116 CSLCs. Among these genes, notably, platelet-derived growth factor A (PDGFA) and signal transducer and activator of transcription 3 (STAT3) were relevant according to the cancer pathway analyzed using NetworkAnalyst. Furthermore, therapeutic screening revealed that the agents targeting STAT3 and Wnt signaling pathways were efficient in reducing the cell viabilities of both HCT116 and HT29 cells. Consequently, we discovered that STAT3 inhibition using homoharringtonine and STAT3 knockdown significantly reduced the formation and survival of HT29-derived tumorspheres. We also observed that STAT3 phosphorylation was regulated by epidermal growth factor (EGF) to induce PDGFA and Wnt signaling cascades. Conclusions: We identified the potential genes involved in tumorsphere formation and survival in selective EGFR-positive CRCs. The results reveal that the EGF-STAT3 signaling pathway promotes and maintains CRC stemness. In addition, a crosstalk between STAT3 and Wnt activates the Wnt/β-catenin signaling pathway, which is also responsible for cancer stemness. Thus, STAT3 is a putative therapeutic target for CRC treatment.",
keywords = "Cancer stem cell, EGFR, LGR5, PDGFA, STAT3, Wnt",
author = "Cheng, {Chun Chia} and Liao, {Po Nien} and Ho, {Ai Sheng} and Lim, {Ken Hong} and Jungshan Chang and Su, {Ying Wen} and Chen, {Caleb Gon Shen} and Chiang, {Ya Wen} and Yang, {Bi Ling} and Lin, {Huan Chau} and Chang, {Yu Cheng} and Chang, {Chun Chao} and Chang, {Yi Fang}",
year = "2018",
month = "8",
day = "2",
doi = "10.1186/s12929-018-0456-y",
language = "English",
volume = "25",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers

T2 - RNAseq analysis and therapeutic screening

AU - Cheng, Chun Chia

AU - Liao, Po Nien

AU - Ho, Ai Sheng

AU - Lim, Ken Hong

AU - Chang, Jungshan

AU - Su, Ying Wen

AU - Chen, Caleb Gon Shen

AU - Chiang, Ya Wen

AU - Yang, Bi Ling

AU - Lin, Huan Chau

AU - Chang, Yu Cheng

AU - Chang, Chun Chao

AU - Chang, Yi Fang

PY - 2018/8/2

Y1 - 2018/8/2

N2 - Background: Cancer stem cells are capable of undergoing cell division after surviving cancer therapies, leading to tumor progression and recurrence. Inhibitory agents against cancer stem cells may be therapeutically used for efficiently eradicating tumors. Therefore, the aim of this study was to identify the relevant driver genes that maintain cancer stemness in epidermal growth factor receptor (EGFR)-positive colorectal cancer (CRC) cells and to discover effective therapeutic agents against these genes. Methods: In this study, EGFR-positive cancer stem-like cells (CSLCs) derived from HCT116 and HT29 cells were used as study models for in vitro inductions. To identify the differential genes that maintain CSLCs, RNAseq analysis was conducted followed by bioinformatics analysis. Moreover, a panel containing 172 therapeutic agents targeting the various pathways of stem cells was used to identify effective therapeutics against CSLCs. Results: RNAseq analysis revealed that 654 and 840 genes were significantly upregulated and downregulated, respectively, in the HCT116 CSLCs. Among these genes, notably, platelet-derived growth factor A (PDGFA) and signal transducer and activator of transcription 3 (STAT3) were relevant according to the cancer pathway analyzed using NetworkAnalyst. Furthermore, therapeutic screening revealed that the agents targeting STAT3 and Wnt signaling pathways were efficient in reducing the cell viabilities of both HCT116 and HT29 cells. Consequently, we discovered that STAT3 inhibition using homoharringtonine and STAT3 knockdown significantly reduced the formation and survival of HT29-derived tumorspheres. We also observed that STAT3 phosphorylation was regulated by epidermal growth factor (EGF) to induce PDGFA and Wnt signaling cascades. Conclusions: We identified the potential genes involved in tumorsphere formation and survival in selective EGFR-positive CRCs. The results reveal that the EGF-STAT3 signaling pathway promotes and maintains CRC stemness. In addition, a crosstalk between STAT3 and Wnt activates the Wnt/β-catenin signaling pathway, which is also responsible for cancer stemness. Thus, STAT3 is a putative therapeutic target for CRC treatment.

AB - Background: Cancer stem cells are capable of undergoing cell division after surviving cancer therapies, leading to tumor progression and recurrence. Inhibitory agents against cancer stem cells may be therapeutically used for efficiently eradicating tumors. Therefore, the aim of this study was to identify the relevant driver genes that maintain cancer stemness in epidermal growth factor receptor (EGFR)-positive colorectal cancer (CRC) cells and to discover effective therapeutic agents against these genes. Methods: In this study, EGFR-positive cancer stem-like cells (CSLCs) derived from HCT116 and HT29 cells were used as study models for in vitro inductions. To identify the differential genes that maintain CSLCs, RNAseq analysis was conducted followed by bioinformatics analysis. Moreover, a panel containing 172 therapeutic agents targeting the various pathways of stem cells was used to identify effective therapeutics against CSLCs. Results: RNAseq analysis revealed that 654 and 840 genes were significantly upregulated and downregulated, respectively, in the HCT116 CSLCs. Among these genes, notably, platelet-derived growth factor A (PDGFA) and signal transducer and activator of transcription 3 (STAT3) were relevant according to the cancer pathway analyzed using NetworkAnalyst. Furthermore, therapeutic screening revealed that the agents targeting STAT3 and Wnt signaling pathways were efficient in reducing the cell viabilities of both HCT116 and HT29 cells. Consequently, we discovered that STAT3 inhibition using homoharringtonine and STAT3 knockdown significantly reduced the formation and survival of HT29-derived tumorspheres. We also observed that STAT3 phosphorylation was regulated by epidermal growth factor (EGF) to induce PDGFA and Wnt signaling cascades. Conclusions: We identified the potential genes involved in tumorsphere formation and survival in selective EGFR-positive CRCs. The results reveal that the EGF-STAT3 signaling pathway promotes and maintains CRC stemness. In addition, a crosstalk between STAT3 and Wnt activates the Wnt/β-catenin signaling pathway, which is also responsible for cancer stemness. Thus, STAT3 is a putative therapeutic target for CRC treatment.

KW - Cancer stem cell

KW - EGFR

KW - LGR5

KW - PDGFA

KW - STAT3

KW - Wnt

UR - http://www.scopus.com/inward/record.url?scp=85051077111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051077111&partnerID=8YFLogxK

U2 - 10.1186/s12929-018-0456-y

DO - 10.1186/s12929-018-0456-y

M3 - Article

VL - 25

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 1

M1 - 60

ER -